Combining CRISPrs with Comparative genomics; a gateway to rapidly unlocking the effects of genetic and epigenetic variation on the galaninergic system
The galaninergic system modulates appetite, pain, and mood making the system an excellent target for the development of drugs against obesity, chronic pain and depression. However, genetic analysis has only had limited success in associating specific coding sequence variants with disease susceptibility and the effects of epigenetic modification on the galaninergic system has hardly begun. Using comparative genomics we identified an enhancer region 42kb 5 ’ of the GAL gene coding region; called GAL5.1, that was active in paraventricular nucleus (PVN), amygdala and dorsal root ganglia (DRG).
Source: Neuropeptides - Category: Neuroscience Authors: Alasdair MacKenzie, Elizabeth Hay Source Type: research
More News: Brain | Chronic Pain | Depression | Eating Disorders & Weight Management | Genetics | Neurology | Obesity | Pain